Logo

Incyte Reports the US FDA's Acceptance of NDA for Parsaclisib to Treat R/R Non-Hodgkin Lymphomas

Share this

Incyte Reports the US FDA's Acceptance of NDA for Parsaclisib to Treat R/R Non-Hodgkin Lymphomas

Shots:

  • The submission is based on P-II studies i.e., CITADEL-203/204/205 that evaluate parsaclisib in patients with r/r FL, MZL & MCL. The anticipated PDUFA date for parsaclisib in adult patients with r/r FL is Aug 30, 2022.
  • The results from the studies showed that Parsaclisib was generally well-tolerated with a manageable safety profile
  • The FDA grants the priority review of parsaclisib for r/r MZL who have received at least one prior anti-CD20-based regimen & for MCL who have received at least one prior therapy & the designation shortens the review period by 4mos. as compared to standard review. The anticipated PDUFA date is April 30, 2022 to­ / article

                    Ref: Incyte | Image: Incyte

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions